clinical trial · NCT03186456
The Safety and Efficacy of Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife®-ACI) in the Treatment of Acute Cerebral Infarction
Sclnow Biotechnology Co., Ltd.·phase1·suspended·n = 40
Cerebral InfarctionAllogeneic umbilical cord mesenchymal stem cells (SCLnow 19#)Aspirin Tablet
brief summary
The purposes of the study is to determine the safety and efficacy of treating acute ischemic stroke patients with human umbilical cord mesenchymal stem cells (hUC-MSC).
started
Dec 31, 2026
primary completion
Jun 30, 2027
completion
Dec 31, 2027
last updated
Apr 23, 2026
detailed description
This is a randomized, double-blind, paralleled study. 40 patients will be separated into two groups, and receive basic treatment (Aspirin Tablet). Patients in experimental group will receive hUC-MSC once a month, total 3 times. After the treatment, investigator will have follow-up visit for 6 months, evaluate the security and efficacy of hUC-MSC.
official title
Study the Safety and Efficacy of Human Umbilical Cord-derived Mesenchymal Stem Cells in the Treatment of Acute Cerebral Infarction
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol